RESEARCH PAPER
Joint hypermobility in fibromyalgia patients has no impact on tests for disease severity
1
The Parker Institute, Frederiksberg Hospital, Capital Region, Denmark
2
University Library, Copenhagen, Denmark
Corresponding author
Søren Ribel-Madsen
The Parker Institute, Frederiksberg Hospital, Nordre Fasanvej 57, DK-2000 Frederiksberg, Denmark.
The Parker Institute, Frederiksberg Hospital, Nordre Fasanvej 57, DK-2000 Frederiksberg, Denmark.
J Pre Clin Clin Res. 2008;2(2):122-126
KEYWORDS
ABSTRACT
Benign joint hypermobility appears more frequently in fibromyalgia patients than in a comparable healthy cohort. The aim of this study was to investigate if fibromyalgia patients also diagnosed with benign joint hypermobility may be a distinct subgroup in the fibromyalgia population.The presence of benign joint hypermobility was determined in a population of 27 fibromyalgia patients. Relevant anatomical, physiological and biochemical parameters were measured, and specific fibromyalgia criteria were assessed for each patient. 15 patients suffered from benign joint hypermobility. In general, the presence of benign joint hypermobilty did not change the disease appearance in fibromyalgia patients. This applied to the main characteristics – pain (p=0.6), muscle strength (p=0.6), hydroxyproline in skin (p=0.99), or collagen markers in urine CTX-I and CTX-II (p=0.45 and 0.41, respectively) – as well as to other studied variables. The only difference found between the two groups was in concentrations of plasma electrolytes with a higher potassium concentration level and lower sodium to potassium ratio in the hypermobile group (p=0.026), which showed the same mean as seen in the healthy population. Benign joint hypermobility with fibromyalgia does not change the fibromyalgia disease characteristics, and hypermobile fibromyalgia patients do not appear to differ in disease severity from the rest of the fibromyalgia population.
REFERENCES (33)
1.
Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, Tugwell P, Campbell SM, Abeles M, Clark P, et al: The American College of Rheumatology 1990 Criteria for the classifi cation of fi bromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 1990, 33(2), 160-172.
2.
Acasuso-Diaz M, Collantes-Estevez E: Joint hypermobility in patients with fi bromyalgia syndrome. Arthritis Care Res 1998, 11(1), 39-42.
3.
Gedalia A, Press J, Klein M, Buskila D: Joint hypermobility and fi bromyalgia in schoolchildren. Ann Rheum Dis 1993, 52(7), 494- 496.
4.
Kirk JA, Ansell BM, Bywaters EG: The hypermobility syndrome. Musculoskeletal complaints associated with generalized joint hypermobility. Ann Rheum Dis 1967, 26(5), 419-425.
5.
Ofl uoglu D, Gunduz OH, Kul-Panza E, Guven Z: Hypermobility in women with fi bromyalgia syndrome. Clin Rheumatol 2006, 25(3), 291-293.
6.
Sendur OF, Gurer G, Bozbas GT: The frequency of hypermobility and its relationship with clinical fi ndings of fi bromyalgia patients. Clin Rheumatol 2007, 26(4), 485-487.
7.
Fitzcharles MA: Is hypermobility a factor in fi bromyalgia? J Rheumatol 2000, 27(7), 1587-1589.
8.
Staud R: Biology and therapy of fi bromyalgia: pain in fi bromyalgia syndrome. Arthritis Res Ther 2006, 8(3), 208.
9.
Staud R, Koo E, Robinson ME, Price DD: Spatial summation of mechanically evoked muscle pain and painful after-sensations in normal subjects and fi bromyalgia patients. Pain 2007, 130(1-2), 177-187.
10.
Staud R, Spaeth M: Psychophysical and neurochemical abnormalities of pain processing in fi bromyalgia. CNS Spectr 2008, 13(3 Suppl 5), 12-17.
11.
Grahame R: Joint hypermobility and genetic collagen disorders: are they related? Arch Dis Child 1999, 80(2), 188-191.
12.
Beighton P, Grahame R, Bird H: Hypermobility of joints. (3rd ed.). Springer, London 1999.
13.
Zweers MC, Hakim AJ, Grahame R, Schalkwijk J: Joint hypermobility syndromes: the pathophysiologic role of tenascin-X gene defects. Arthritis Rheum 2004, 50(9), 2742-2749.
14.
Hakim AJ, Sahota A: Joint hypermobility and skin elasticity: the hereditary disorders of connective tissue. Clin Dermatol 2006, 24(6), 521-533.
15.
Malfait F, Hakim AJ, De Paepe A, Grahame R: The genetic basis of the joint hypermobility syndromes. Rheumatology 2006, 45(5), 502-507.
16.
Gronemann ST, Ribel-Madsen S, Bartels EM, Danneskiold-Samsoe B, Bliddal H: Collagen and muscle pathology in fi bromyalgia patients. Rheumatology 2004, 43(1), 27-31.
17.
Ribel-Madsen S, Gronemann ST, Bartels EM, Danneskiold-Samsoe B, Bliddal H: Collagen structure in skin from fi bromyalgia patients. Int J Tissue React 2005, 27(3), 75-82.
18.
Jacobsen S, Jensen LT, Foldager M, Danneskiold-Samsoe B: Primary fi bromyalgia: Clinical parameters in relation to serum procollagen type III aminoterminal peptide. Br J Rheumatol 1990, 29(3), 174-177.
19.
Ribel-Madsen S, Christgau S, Gronemann ST, Bartels EM, Danneskiold- Samsoe B, Bliddal H: Urinary markers of altered collagen metabolism in fi bromyalgia patients. Scand J Rheumatol 2007, 36(6), 470-477.
20.
Burckhardt CS, Clark SR, Bennett RM: The fi bromyalgia impact questionnaire: development and validation. J Rheumatol 1991, 18(5), 728-733.
21.
Grahame R, Bird HA, Child A: The revised (Brighton 1998) criteria for the diagnosis of benign joint hypermobility syndrome (BJHS). J Rheumatol 2000, 27(7), 1777-1779.
22.
Cohen SA, Bidlingmeyer BA, Tarvin TL: PITC derivatives in amino acid analysis. Nature 1986, 320, 769-770.
23.
Colwell A, Russell RGG, Eastell R: Factors aff ecting the assay of urinary 3-hydroxy pyridinium crosslinks of collagen as markers of bone resorption. Eur J Clin Invest 1993, 23(6), 341-349.
24.
Zerahn B, Bliddal H, Nawrocki A, Borgwardt A, Borum K, Danneskiold- Samsoe B: Bone mass in the calcaneus in patients with fi bromyalgia. J Musculoskeletal Pain 1993, 23(6), 341-349.
25.
Grahame R, Hakim AJ: Hypermobility. Curr Opin Rheumatol 2008, 20(1), 106-110.
26.
Simmonds JV, Keer RJ: Hypermobility and the hypermobility syndrome. Man Ther 2007, 12(4), 298-309.
27.
Remvig L, Jensen DV, Ward RC: Epidemiology of general joint hypermobility and basis for the proposed criteria for benign joint hypermobility syndrome: review of the literature. J Rheumatol 2007, 34(4), 804-809.
28.
Diers M, Koeppe C, Yilmaz P, Thieme K, Markela-Lerenc J, Schiltenwolf M, van Ackern K, Flor H: Pain ratings and somatosensory evoked responses to repetitive intramuscular and intracutaneous stimulation in fi bromyalgia syndrome. J Clin Neurophysiol 2008, 25(3), 153-160.
29.
Nielsen LA, Henriksson KG: Pathophysiological mechanisms in chronic musculoskeletal pain (fi bromyalgia): the role of central and peripheral sensitization and pain disinhibition. Best Pract Res Clin Rheumatol 2007, 21(3), 465-480.
30.
Vierck CJ, Jr: Mechanisms underlying development of spatially distributed chronic pain (fi bromyalgia). Pain 2006, 124(3), 242- 263.
32.
Gulbahar S, Sahin E, Baydar M, Bircan C, Kizil R, Manisah M, Akahn E, Peker O: Hypermobility syndrome increases the risk for low bone mass. Clin Rheumatol 2006, 25(4), 511-514.
33.
Nijs J, van Essche E, de Munck M, Dequeker J: Ultrasonographic, axial, and peripheral measurements in female patients with benign hypermobility syndrome. Calcif Tissue Int 2000, 67(1), 37-40.
| eISSN: | 1898-7516 |
| ISSN: | 1898-2395 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
